Short answer
Cartesian Therapeutics, Inc. (RNAC) filed an 8-K current report with the SEC on September 29, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Additional retreatment data from Phase 2 Descartes-08 trial in myasthenia gravis patients.
Cartesian Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Additional retreatment data from Phase 2 Descartes-08 trial in myasthenia gravis patients
- Press release dated September 29, 2026, contains the disclosed clinical results
- Data update may influence Descartes-08 development outlook and investor assessment of therapeutic durability
Item 8.01 · Other Events
- Five MG patients retreated after symptom recurrence at median 16.6 months following initial Descartes-08 treatment
- Month 12 post-retreatment outcomes: MG-ADL reduction 6.6 points and MGC reduction 15 points from baseline
- All patients achieved clinically meaningful MGC and MG-ADL improvements; four sustained MG-ADL benefit through Month 12
- Retreatment showed no serious adverse events and no cytokine release syndrome, neurotoxicity, cytopenias, or hypogammaglobulinemia
- Findings support potential repeat dosing, strengthening Descartes-08’s durability and retreatment profile in MGેણ
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cartesian Therapeutics, Inc. 8-K filings
Get the next RNAC 8-K as it lands
Follow RNAC for push alerts, or ask the research agent what this filing means.